Home · Solutions
The world’s first MDR-approved AI-solution to improve diagnosis of pancreatic lesions
Non-invasive screening algorithm that anticipates pancreatic, hepatic, and renal cancer by detecting & identifying focal lesions, automating their monitoring.
Sensitivity in Lesions Detection
96,3%
Standard of care surpassed: 96,3% sensitivity & 84,5% specificity**
Proven Technical Feasibility
8 Hospitals
- Proven seamless workflow integration
- Patented internationally for pancreas (WO 2023/030734)
We operate across three key organs
Solution Features
Fully integrable in current workflow
SYCAI MEDICAL works as an AI-based silent assistant providing the latests technological advances to the radiologists fully integrated in their current workflow (zero-click).
Automating the patient temporal evolution
We have the only patent that enables an automatic single-lesion tracking over time, saving time to radiologists and presenting the results in a standardized way
Secure and compliant with norms and regulations
SYCAI MEDICAL is compliant with ISO 13485 and is committed to continuously improve customer satisfaction by delivering high-quality services and ensuring compliance with all applicable regulations
Full abdomen approach
The current platform conception of SYCAI MEDICAL allows us to enable key features to expand to other organs and pathologies on each product updates, offering our current customers a wider range of patients to benefit from the tool
Testimonials
M.D. Manel Escobar
“I believe that SYCAI Medical has a disruptive value proposition focused on anticipating and beating cancer that will become a must in the future of clinical practice. In addition, its price makes it clearly cost-effective, fitting into the budget of any hospital”
Head of Radiology and Imaging Diagnostics
Hospital Vall d’Hebron (Barcelona)
M.D. Josep Munuera
“SYCAI is a digital tool that assists radiologists in the detection of pancreatic lesions, improving diagnostic precision, facilitating and accelerating the image analysis and automating the quantification and monitoring of these lesions, I am sure they will reach their goal and disrupt how radiologists work nowadays”
Chief of Radiology
Hospital Santa Creu i Sant Pau (Barcelona)
